- Home
- RLYB vs NRSN Comparison
RLYB vs NRSN Comparison
Compare RLYB & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- NRSN
- Stock Information
- Founded
- RLYB 2018
- NRSN 2017
- Country
- RLYB United States
- NRSN Israel
- Employees
- RLYB N/A
- NRSN N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- RLYB Health Care
- NRSN Health Care
- Exchange
- RLYB Nasdaq
- NRSN Nasdaq
- Market Cap
- RLYB 25.0M
- NRSN 26.0M
- IPO Year
- RLYB 2021
- NRSN 2021
- Fundamental
- Price
- RLYB $0.25
- NRSN $1.03
- Analyst Decision
- RLYB Hold
- NRSN Hold
- Analyst Count
- RLYB 5
- NRSN 1
- Target Price
- RLYB $11.50
- NRSN N/A
- AVG Volume (30 Days)
- RLYB 194.2K
- NRSN 135.5K
- Earning Date
- RLYB 05-08-2025
- NRSN 04-07-2025
- Dividend Yield
- RLYB N/A
- NRSN N/A
- EPS Growth
- RLYB N/A
- NRSN N/A
- EPS
- RLYB N/A
- NRSN N/A
- Revenue
- RLYB $636,000.00
- NRSN N/A
- Revenue This Year
- RLYB N/A
- NRSN N/A
- Revenue Next Year
- RLYB N/A
- NRSN N/A
- P/E Ratio
- RLYB N/A
- NRSN N/A
- Revenue Growth
- RLYB N/A
- NRSN N/A
- 52 Week Low
- RLYB $0.22
- NRSN $0.51
- 52 Week High
- RLYB $2.00
- NRSN $1.73
- Technical
- Relative Strength Index (RSI)
- RLYB 22.80
- NRSN 49.96
- Support Level
- RLYB $0.24
- NRSN $1.00
- Resistance Level
- RLYB $0.28
- NRSN $1.04
- Average True Range (ATR)
- RLYB 0.06
- NRSN 0.09
- MACD
- RLYB -0.02
- NRSN 0.01
- Stochastic Oscillator
- RLYB 6.12
- NRSN 76.25
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.